Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023)
Revolution Medicines' EBITDA Margin came in at -24040.97% for Q4 2023, down 23647.89 percentage points from -393.08% a year earlier.
Powered by 
Analysis
Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023) Analysis & Trends
For FY2023, Revolution Medicines' EBITDA Margin was -4154.08%, down 3438.41 percentage points from FY2022.
- EBITDA Margin has declined in each of the last four years, with a five-year change of -3962.84 percentage points (FY2018 to FY2023).
- Going back by year, EBITDA Margin was -715.68% in FY2022 (-90.27 pp), -625.41% in FY2021 (-376.51 pp), -248.90% in FY2020 (-147.49 pp) and -101.41% in FY2019 (+89.84 pp).
- The Q4 2023 figure represents the lowest quarterly EBITDA Margin in data going back to Q1 2019.
- Year-over-year, EBITDA Margin increased in two of the last seven quarters, with an average year-over-year change of -3428.96 percentage points.
- The fastest year-over-year change in EBITDA Margin over five years came in Q3 2022 (a gain of 2487.32 percentage points), and the weakest in Q4 2023 (a drop of 23647.89 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,122.91 Bn | 1,091.50 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 615.09 Bn | 533.62 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 504.75 Bn | 477.86 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 360.18 Bn | 314.55 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 292.05 Bn | 256.04 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 256.09 Bn | 229.78 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 233.63 Bn | 189.02 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.49 Bn | 168.69 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 168.35 Bn | 114.99 Bn | 10.94 Bn | 39.16% |
| 10 | Revolution Medicines | 37.70 Bn | 27.90 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -24,040.97% |
| Jun 30, 2023 | -2,805.28% |
| Mar 31, 2023 | -1,050.07% |
| Dec 31, 2022 | -393.08% |
| Sep 30, 2022 | -2,242.01% |
| Jun 30, 2022 | -667.60% |
| Mar 31, 2022 | -748.85% |
| Dec 31, 2021 | -547.38% |
| Sep 30, 2021 | -4,729.34% |
| Jun 30, 2021 | -499.33% |
| Mar 31, 2021 | -359.55% |
| Dec 31, 2020 | -378.32% |
| Sep 30, 2020 | -209.98% |
| Jun 30, 2020 | -269.77% |
| Mar 31, 2020 | -174.81% |
| Dec 31, 2019 | -154.43% |
| Sep 30, 2019 | -101.18% |
| Jun 30, 2019 | -79.12% |
| Mar 31, 2019 | -73.24% |
API Access
Revolution Medicines EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RVMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "RVMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RVMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();